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Acute promyelocytic leukemia (APL), a cytogenetically distinct subtype of acute myeloid leukemia (AML), characterized by the t(15;17)-associated PML-RARA fusion, has been successfully treated with therapy utilizing all-trans-retinoic acid (ATRA) to differentiate leukemic blasts. However, among patients with non-APL AML, ATRA-based treatment has not been effective. Here we show that, through epigenetic reprogramming, inhibitors of lysinespecific demethylase 1 (LSD1, also called KDM1A), including tranylcypromine (TCP), unlocked the ATRA-driven therapeutic response in non-APL AML. LSD1 inhibition did not lead to a large-scale increase in histone 3 Lys4 dimethylation (H3K4 me2 ) across the genome, but it did increase H3K4 me2 and expression of myeloid-differentiation-associated genes. Notably, treatment with ATRA plus TCP markedly diminished the engraftment of primary human AML cells in vivo in nonobese diabetic (NOD)-severe combined immunodeficient (SCID) mice, suggesting that ATRA in combination with TCP may target leukemia-initiating cells. Furthermore, initiation of ATRA plus TCP treatment 15 d after engraftment of human AML cells in NOD-SCID g (with interleukin-2 (IL-2) receptor g chain deficiency) mice also revealed the ATRA plus TCP drug combination to have a potent anti-leukemic effect that was superior to treatment with either drug alone. These data identify LSD1 as a therapeutic target and strongly suggest that it may contribute to AML pathogenesis by inhibiting the normal pro-differentiative function of ATRA, paving the way for new combinatorial therapies for AML.
AML currently accounts for approximately 80% of all adult acute leukemias, with a median age at diagnosis of 67 years (ref. 1) . Although clinical advances in AML have been made, treatment failure in non-APL AML remains high, with a particularly poor prognosis commonly seen in the elderly, in patients with certain subtypes of AML and in patients with secondary AML after cancer therapy 2 . Moreover, given projected improvements in life expectancy in the general population and, concomitantly, an increase in the frequency of AML (with a 38% increase in elderly cases predicted by 2031), the development of new and effective anti-AML therapies is clearly required 1 . ATRA has held great promise in both cancer treatment and prevention 3 , and research strategies that seek to extend the efficacy of ATRA-based treatment to non-APL AML are key avenues of investigation 4 . Evidence points to one of the underlying reasons for ATRA resistance in AML as a failure of ATRA to induce proper transcriptional activation of retinoic acid receptor (RAR) target genes, such as TNFSF10 (ref. 5) and RARA2 (ref. 6 ). An epigenetic analysis of primary AML samples revealed that relative to normal CD33 + cells, loss of RARα2 expression in AML is associated with a reduction in H3K4 me2 on the RARA2 promoter 7 (a modification that is associated with transcriptional activation) 8 . The mono-and di-methyl lysine demethylase LSD1 (KDM1A) 9 is highly expressed in patients with AML (http://www.proteinatlas.org/) 10 , and its overexpression has been implicated in various other tumors 11, 12 . Collectively, these data predicted that the use of small-molecule inhibitors that target LSD1 (LSD1i) could result in epigenetic reprogramming that enhanced or facilitated the execution of the ATRA-induced differentiation program in AML cells. We tested two structurally unrelated compounds, trans-2-phenylcyclopropylamine (tranylcypromine, or TCP) 13 , which is a time-dependent, mechanism-based irreversible inhibitor of LSD1, and a non-competitive LSD1 inhibitor, 1,15-bis{N5- [3,3-(diphenyl) propyl]-N1-biguanido}-4,12-diazapentadecane (the biguanide polyamine analog 2d) 14 .
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For the in vitro studies, we focused on the ATRA-responsive HL-60 AML M2 (ref. 15 ) cell line and on ATRA-insensitive TEX cells, which are derived from primitive human cord blood cells immortalized by expression of the FUS (TLS)-ERG oncogene 16 . TEX cells mimic the features of primary human AML and of leukemia-initiating cells (LIC) and are more than 90% CD34 +16 . Treatment with ATRA and TCP increased the fraction of cells expressing the myeloid differentiation marker CD11b (which regulates leukocyte adhesion and migration to mediate the inflammatory response) by 21-fold and by 16-fold in HL-60 and TEX cells, respectively (Fig. 1a) . We obtained similar results for ATRA-responsive U937 cells and the ATRA-insensitive CD34 + KG-1a (ref. 17) cell line (Supplementary Fig. 1 ). Although 2 days of treatment with ATRA plus 2d or TCP had little effect on apoptosis in either of the cell lines tested (Supplementary Fig. 2a) , after 4 days with the ATRA plus 2d or TCP combinations, we observed early or late apoptosis in 55% of TEX cells, with only a minor increase in apoptosis in p53-null 18 HL-60 cells (Supplementary Fig. 2b ). These findings together with the gene expression pathway analysis Table 1 ) are consistent with the onset of postdifferentiation cell death 5, 6 , facilitated by the presence of p53 in TEX cells 19 . Treatment with ATRA and LSD1i led to a marked increase in respiratory burst activity in HL-60 cells (Fig. 1b) and induced the nuclear lobulation that is associated with neutrophilic differentiation in both HL-60 and TEX cells (Fig. 1c) .
Mirroring the results in the cell lines, treatment with ATRA and TCP increased the fraction of CD11b + cells in primary AML samples by a factor of up to 11-fold (Fig. 1d and Supplementary Table 2) . Treatment with ATRA plus LSD1i also induced differentiation-associated morphological changes, including the formation of cytoplasmic neutrophil granules (Fig. 1d) . In agreement with previously reported findings 20 , treatment with ATRA alone had, in general, only a limited effect in primary AML samples, and treatment with TCP alone resulted in minimal activity in most samples. Confirming a direct role for LSD1 in myeloid differentiation, shRNA knockdown of LSD1 markedly potentiated the ability of ATRA to induce the expression of CD11b in HL-60 and TEX cells (Fig. 1e and Supplementary Figs. 3  and 4) . Given that TCP also inhibits the related H3K4 demethylase LSD2 (ref. 13 ), which shares homology in the enzymatic domain with LSD1, we also performed knockdown of LSD2 ( Fig. 1e and Supplementary Figs. 3 and 4) . Although knockdown of LSD2 did increase the effect of ATRA in both HL-60 and TEX cells, it was much less effective at potentiating CD11b expression compared with shRNA knockdown of LSD1.
Given that TCP enhanced the effects of ATRA in myeloid differentiation of AML cells more effectively than 2d did, and also taking into consideration that it is already licensed for use as an antidepressant, we focused our subsequent studies on TCP. An in vitro colony formation assay showed that although treatment with either TCP or ATRA alone had a small effect in HL-60 cells, treatment with ATRA and TCP together reduced the clonogenic capacity of the HL-60 cells by 70% compared to treatment with ATRA alone (Fig. 2a) . Consistent with this finding, when we treated HL-60 cells in which LSD1 was knocked down with ATRA, they also showed a reduction in clonogenic capacity of 40% compared to treatment with ATRA alone (Fig. 2a) . Notably, we confirmed these in vitro data using NOD-SCID mice transplanted intrafemorally with primary AML samples (FAB M1 (ICD-O M9873/3)) treated with ATRA or ATRA plus TCP ex vivo for 16 h prior to transplantation and with the same drug regimens in vivo from day 1 after transplantation. Given that TCP showed only minimal activity as a single agent in the majority of primary AML samples tested (Supplementary Table 2) , we did not include it alone in this series of experiments. Here the ATRA plus TCP combination markedly diminished leukemic engraftment in both the injected right femur as well as the non-injected bone marrow sites of the mice (Fig. 2b and Supplementary Figs. 5 and 6) . A disseminated 5-week AML graft can only be generated in vivo by LIC 21, 22 , and prior studies have shown that migration and hematopoietic engraftment of noninjected bone marrow sites requires intact stem/progenitor cell function 23, 24 . Thus, the substantially reduced or absent migration and engraftment seen in the distal bone marrow of mice treated with ATRA plus TCP compared to that of untreated mice or mice treated with ATRA alone indicates that the combination regimen eliminated the LICs or severely impaired their function. Furthermore, consistent with the finding that ATRA in combination with TCP did not induce apoptosis in mononuclear cells from the bone marrow of normal healthy human donors in vitro (both total mononuclear cells and CD34 + progenitors; Supplementary Fig. 7) , treatment with ATRA plus TCP had no toxic effects on normal cord-blood-derived hematopoietic stem or progenitor cells transplanted into NOD-SCID mice ( Fig. 2b and Supplementary Figs. 6 and 8) .
To evaluate the ability of the ATRA plus TCP combination treatment to reduce tumor burden, we initiated this treatment 15 d after transplantation in NOD-SCID γ (NSG) mice. The results in the NSG mice mirrored those obtained in the NOD-SCID mice in which treatment was initiated on day 1, with ATRA and TCP showing some activity when used as single agents, but with ATRA plus TCP proving more effective than either alone, in particular where we obtained higher levels of engraftment from untreated mice (primary AML sample #090240) ( Fig. 2c and Supplementary Fig. 9 ). Additionally, we performed secondary transplants with right femur and bone marrow cells from NSG mice after treatment (AML sample #0840). NSG mice transplanted with cells from mice treated with ATRA plus TCP did not engraft in untreated secondary recipients, indicating that this treatment eliminated tumorigenicity (Fig. 2d) . However, cells from ATRA-treated mice also did not engraft in secondary mouse recipients (Fig. 2d) . It is unclear whether this result was caused by an unexpected efficacy of ATRA toward this particular AML sample or whether higher levels of engraftment would have resulted in a more potent differential effect for treatment with ATRA plus TCP (as observed in Fig. 2b) , and further studies will be required to address this issue.
Given that LSD1 is an epigenetic modifier associated primarily with transcriptional silencing, we analyzed the effects of ATRA, TCP or both in combination on gene expression. A hierarchical clustering analysis of the 500 genes that showed the greatest differential response to drug treatments in HL-60 or TEX cells revealed that the majority of these genes were regulated concordantly by ATRA and TCP in the same direction (albeit with TCP alone exerting a lesser effect in TEX cells) and, furthermore, that this regulation was strengthened by the combination of the two drugs (Fig. 3a) . Consistent with these findings, the changes in global gene expression induced by treatment with ATRA, TCP or both in combination correlated in HL-60 and TEX cells (Fig. 3b) . We also compared the distribution of gene expression intensities between HL-60 cells treated with TCP and those transduced with LSD1 shRNA. This comparison revealed a remarkable association (Fig. 3c ) that was consistent with biological data indicating that LSD1 knockdown and TCP treatment had broadly ACTB  ANXA2  BHLHB2  CCR2  CD1D  CD300LF  CD48  CD58  CD86  CEACAM1  CECR1  CKLF  CREB1  CTSH  FAIM3  FUCA1  GFI1  GIMAP4  GLIPR1  GPR82  HLA-DMB  ITGAM  ITGAX  LILRA5  LST1  LTB  LY96  MS4A6A  NAPSB  PLXNA1  PRAM1  RAB37  RARA2  SNRK  SPI1  STX3  TNFSF10 similar effects on ATRA-induced differentiation (Fig. 1) . We also analyzed genes regulated in the same direction in both HL-60 and TEX cells and found that similar subsets of genes were altered in both cell lines after drug treatments (Fig. 3d, Supplementary Fig. 10 and Supplementary Data 1). When we further functionally analyzed these subsets, we found that they contained genes associated with the myeloid developmental program or with apoptosis (Supplementary We next examined the effects of treatment with ATRA, TCP and ATRA plus TCP on H3K4 me2 genome wide. Although we found no genome-wide increase in H3K4 me2 in response to LSD1 inhibition, we found unique H3K4 me2 clusters after the drug treatments (Fig. 4a) . Although treatment with ATRA or TCP alone led to an increase in H3K4 me2 , the combined treatment had an even greater effect both genome wide and within the gene promoter and 5′ transcribed regions (-2,000 to +2,000 bp from transcriptional start sites). These data are consistent with the results previously obtained after deletion of Kdm1a (also known as Aof2) in mouse embryonic stem cells in which the total amounts of H3K4 me2 remained unchanged but in which 4% of promoters were found to gain dimethyl H3K4 (ref. 28 ). We found a positive correlation between upregulation of gene expression and H3K4 me2 , with genes that gained clusters in promoter regions after treatments being more highly expressed in treated samples than in untreated samples (P < 0.001) and vice versa (that is, genes that did not gain H3K4 me2 clusters were more highly expressed in untreated samples (P = 0.043)). Furthermore, in genes associated with the myeloid differentiation program that are upregulated by treatment with ATRA plus TCP, our chromatin immunoprecipitation sequencing (ChIPSeq) analysis revealed a strong correlation with increased amounts of H3K4 me2 at -2,000 or +2,000 bp from transcriptional start sites (Fig. 4b,c, Supplementary Table 3 and Supplementary Fig. 11 ).
Drugs targeting aberrant but reversible epigenetic modifications (so called 'epi drugs') have therapeutic potential, and epigenetic enzymes such as DNA methyltransferases, histone deacetylases or histone methyltransferases or demethylases are bona fide targets for anti-AML drug development 4, 29 . Recently, several groups have developed new small-molecule LSD1is based on monoamine oxidase inhibitors (of which TCP is an example), biguanide polyamine analogs or oligoamine analogs [30] [31] [32] [33] [34] , and these efforts may yield results that lead to future treatments with greater specificity and potency than TCP. At present, however, TCP has a major advantage over other LSD1i in development in that it is well tolerated by patients and has been used as an antidepressant and anxiolytic agent since 1960 (sold under the brand names Parnate and Jatrosom) 35 . Furthermore, the TCP concentration used in this study is representative of the range of peak plasma concentrations reported in patients treated with this drug 35 . In summary, these data show the existence of therapeutically relevant crosstalk between the ATRAinduced differentiation pathway and histone H3K4 methylation and that targeting LSD1 in combination with ATRA may be a promising treatment for AML.
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Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/. Accession codes. Raw and normalized expression data are deposited in the Gene Expression Omnibus (GEO) with the accession number GSE34672. ChIP-Seq data are deposited in the GEO with the accession number GSE34726. Data are also deposited in the Leukemia Gene Atlas (http://www.leukemia-gene-atlas.org/).
